Inactive Instrument

Erin Resources Ltd Share Price Australian S.E.

Equities

AU000000ERI2

Pharmaceuticals

End-of-day quote Australian S.E.
- AUD - Intraday chart for Erin Resources Ltd

Financials

Sales 2022 4.73M 3.17M 249M Sales 2023 3.39M 2.27M 179M Capitalization 16.75M 11.21M 883M
Net income 2022 -20M -13.38M -1.05B Net income 2023 -20M -13.38M -1.05B EV / Sales 2022 9.75 x
Net Debt 2022 2.47M 1.65M 130M Net Debt 2023 9.51M 6.37M 501M EV / Sales 2023 7.75 x
P/E ratio 2022
-2.02 x
P/E ratio 2023
-0.7 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 9.44%
More Fundamentals * Assessed data
Managers TitleAgeSince
Founder 44 20/10/05
Chief Operating Officer 53 03/10/22
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Founder 44 20/10/05
Director/Board Member - 31/05/23
Director/Board Member - 11-30
More insiders
Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
More about the company